|
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 0.75 USD | 0.00% |
|
-0.13% | +2.04% |
| 2023 | NGM Biopharmaceuticals Says Phase 2b Trial of Potential Cirrhosis Treatment Meets Primary Endpoint | MT |
| 2023 | Alpine 4 Holdings, Inc.(NasdaqCM:ALPP) dropped from S&P Global BMI Index | CI |
Alpine 4 Holdings, Inc. reported earnings results for the first quarter ended March 31, 2023. For the first quarter, the company reported sales was USD 24.36 million compared to USD 25.59 million a year ago. Net loss was USD 5.77 million compared to USD 4 million a year ago.
Basic loss per share from continuing operations was USD 0.23 compared to USD 0.17 a year ago. Diluted loss per share from continuing operations was USD 0.23 compared to USD 0.17 a year ago.
| 1st Jan change | Capi. | |
|---|---|---|
| +2.04% | 20.26M | |
| +12.06% | 107B | |
| -0.62% | 29.43B | |
| +12.05% | 22.21B | |
| -16.05% | 17.75B | |
| -6.34% | 17.25B | |
| +8.74% | 15.28B | |
| -4.89% | 12.2B | |
| -2.85% | 10.42B | |
| -8.86% | 9.04B |
ALPINE 4 HOLDINGS, INC. 
